公开(公告)号：US20230133566A1

公开(公告)日：2023-05-04

申请号：US17991154

申请日：2022-11-21

申请人： Teclison Limited

发明人： Ruey-min Lee

IPC分类号： A61K31/53 ,  A61K35/17 ,  A61K39/395 ,  C07K16/28 ,  A61K31/09 ,  A61K31/485 ,  A61P35/00 ,  A61K31/05 ,  A61K31/136 ,  A61K31/27 ,  A61K31/352

摘要： Disclosed herein are methods and compositions for enhancing an immune response to a solid tumor in a subject. In some embodiments, a method comprises: (a) administering to the subject a hypoxia-activated bioreductive agent (HABA); (b) inducing hypoxia by (i) administering a hypoxia-inducing agent to the subject or (ii) embolizing one or more blood vessels supplying the solid tumor; and (c) administering an immune checkpoint inhibitor prior to, simultaneously with, or subsequent to step (b) in an amount effective to enhance an immune response to the solid tumor, as compared to an immune response in the absence of the immune checkpoint inhibitor. Kits for use in the disclosed methods are also provided.

公开(公告)号：US20230131271A1

公开(公告)日：2023-04-27

申请号：US18066694

申请日：2022-12-15

申请人： Duke University

发明人： Suzanne E. Wardell ,  Erik R. Nelson ,  Donald P. McDonnell

IPC分类号： A61K31/137 ,  A61K45/06 ,  A61K31/136 ,  C07C217/78 ,  C07C217/84 ,  A61K31/138 ,  A61K31/40 ,  A61K31/4196 ,  A61K31/565 ,  A61K31/5685 ,  A61K31/4535 ,  A61K9/00

摘要： Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

公开(公告)号：US11607395B2

公开(公告)日：2023-03-21

申请号：US17125741

申请日：2020-12-17

申请人： CURASEN THERAPEUTICS, INC.

发明人： Anthony P. Ford ,  Gabriel Vargas

IPC分类号： A61K31/136 ,  A61K31/138 ,  A61P25/16 ,  A61P25/24 ,  A61P25/28

摘要： In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and/or treating a neurodegenerative disease in a patient and treating such patient. More specifically, the disclosure in some embodiments includes administration of a β-AR agonist and a peripherally acting β-blocker (PABRA) to a patient in need thereof.

公开(公告)号：US20230061116A1

公开(公告)日：2023-03-02

申请号：US17792591

申请日：2021-01-13

申请人： Mayo Foundation for Medical Education and Research

发明人： Isobel A. Scarisbrick ,  Erin M. Triplet

IPC分类号： A61K38/08 ,  A61K31/443 ,  A61K31/438 ,  A61K31/136 ,  A61P3/06

摘要： Materials and methods for regulating lipid abundance by modulating Protease Activated Receptor 1 (PAR1) and Protease Activated Receptor 2 (PAR2) levels arc provided herein. In a first aspect, this document features a method that includes (a) identifying a mammal as having a condition characterized at least by impaired lipid production, impaired cholesterol production, or both impaired lipid production and impaired cholesterol production; and (b) administering to the mammal an inhibitor of PAR1 and/or PAR2 in an amount effective to increase lipid production and/or cholesterol production in the mammal.

公开(公告)号：US11583543B2

公开(公告)日：2023-02-21

申请号：US16631266

申请日：2018-07-14

申请人： NeueRe, LLC

发明人： Stephen Anderson

IPC分类号： A61K31/7036 ,  A61P39/00 ,  A61K31/136

摘要： Compositions and methods for extending life expectancy are described herein. Specifically, ambroxol, ambroxol hydrochloride, and/or bromhexine can be used in a method for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the healthspan, lifespan, and/or mental acuity of a subject.

公开(公告)号：US20230035491A1

公开(公告)日：2023-02-02

申请号：US17785385

申请日：2020-12-15

申请人： Baruch S. Blumberg Institute

发明人： Richard G. Pestell ,  Anthony Wayne Ashton

IPC分类号： A61K31/704 ,  A61K39/395 ,  A61K31/136 ,  A61K31/506 ,  A61K31/4706 ,  A61K31/517 ,  A61K31/439 ,  A61P35/00

摘要： Described herein are methods for administering a chemotherapeutic agent to a patient in need thereof comprising administering an effective amount of a CCR5 antagonist contemporaneously with an effective amount of a chemotherapeutic agent. Also described are kits and compositions useful to implement the methods.

公开(公告)号：US11534505B2

公开(公告)日：2022-12-27

申请号：US15984311

申请日：2018-05-18

申请人： D. WESTERN THERAPEUTICS INSTITUTE, INC.

发明人： Makoto Takahagi ,  Nobuhiro Haga ,  Atsushi Inoue

IPC分类号： A61K49/00 ,  C09B11/12 ,  A61K31/13 ,  A61K31/136

摘要： A composition containing Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, and a positional isomer of Brilliant Blue G (BBG) or a pharmaceutically acceptable salt thereof, the composition containing 90 wt % or more and 100 wt % or less of one or both of Brilliant Blue G (BBG) and the pharmaceutically acceptable salt thereof in the total of the Brilliant Blue G (BBG), the pharmaceutically acceptable salt of Brilliant Blue G (BBG), the positional isomer of Brilliant Blue G (BBG), and the pharmaceutically acceptable salt of the positional isomer of Brilliant Blue G (BBG), a method for producing said composition, and a method of removing the ocular membrane of a human patient.

公开(公告)号：US11534445B2

公开(公告)日：2022-12-27

申请号：US15956702

申请日：2018-04-18

申请人： Teclison Limited

发明人： Ruey-min Lee

IPC分类号： A61K31/53 ,  A61K35/17 ,  A61K39/395 ,  C07K16/28 ,  A61K31/09 ,  A61K31/485 ,  A61P35/00 ,  A61K31/05 ,  A61K31/136 ,  A61K31/27 ,  A61K31/352 ,  A61K39/00

摘要： Disclosed herein are methods and compositions for enhancing an immune response to a solid tumor in a subject. In some embodiments, a method comprises: (a) administering to the subject a hypoxia-activated bioreductive agent (HABA); (b) inducing hypoxia by (i) administering a hypoxia-inducing agent to the subject or (ii) embolizing one or more blood vessels supplying the solid tumor; and (c) administering an immune checkpoint inhibitor prior to, simultaneously with, or subsequent to step (b) in an amount effective to enhance an immune response to the solid tumor, as compared to an immune response in the absence of the immune checkpoint inhibitor. Kits for use in the disclosed methods are also provided.

公开(公告)号：US20220395454A1

公开(公告)日：2022-12-15

申请号：US17776168

申请日：2019-12-02

申请人： CHIESI FARMACEUTICI S.P.A.

发明人： Enrico ZAMBELLI ,  Sauro BONELLI ,  Diego COPELLI ,  Massimiliano DAGLI ALBERI ,  Francesca USBERTI

IPC分类号： A61K9/00 ,  A61K31/136 ,  A61K31/4015 ,  A61K31/573 ,  A61K47/10 ,  A61K47/02 ,  A61M15/00

摘要： The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

公开(公告)号：US20220313839A1

公开(公告)日：2022-10-06

申请号：US17727549

申请日：2022-04-22

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Kam W. Leong ,  Yeh-Hsing Lao ,  Tzu-Chieh Ho ,  Smruthi Suryaprakash

IPC分类号： A61K47/69 ,  A61K47/55 ,  A61K47/64 ,  A61K47/68 ,  A61K47/54 ,  A61K47/60 ,  A61P35/02 ,  A61K31/136 ,  A61K31/4178 ,  A61K31/7105 ,  A61K38/46 ,  A61K48/00 ,  C12N15/88

摘要： The present invention discloses a multifunctional DNA-templated micelle system that has a payload carrier of at least a DNA bridge and a functionalized polyethylene glycol (PEG) segment. The micelle can be used to deliver molecules, such as drugs and polynucleotides, to targeted cells for pharmaceutical uses. The PEG segment provides a functional group, such as amine, for ligand conjugation. The DNA-templated micelle of the present invention is highly controllable in size, loading efficiency and tissue targeting, and can carry multiple payloads for targeted combination strategies in cancer therapy, such as gene delivery, gene therapy, and immunotherapy.